Enhertu has shown 'unprecedented' trial results, giving hope to mums like Maggie Ngatai.
Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.
Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu ...
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
WILMINGTON, Del.--(BUSINESS WIRE)--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial ...
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...
The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results